MDMA-assisted therapy is positioned to become the first-in-class FDA-approved psychedelic-assisted therapy. MAPS also sponsors research of MDMA in the treatment of other clinical indications, as well as research into the safety and efficacy of other psychedelic compounds including cannabis, ibogaine, and ayahuasca to treat a range of mental health conditions. This study is currently in Phase 3 clinical trials, as well as limited availability through the Expanded Access and Compassionate Use authorizations in the US and Israel. MAPS’ primary focus is developing MDMA-assisted therapy into an FDA-approved treatment for posttraumatic stress disorder (PTSD). MAPS' Phase 2 clinical trials of MDMA-assisted psychotherapy for the treatment of PTSD have generated preliminary evidence that this treatment is effective and safe MAPS was founded in 1986, the year after MDMA became criminalized, to develop MDMA into a legal medicine based on medical research. The motivation of this prohibition was due to MDMA's increasing use as a recreational street drug with DEA ignorant of MDMA's therapeutic use, which was also criminalized. Drug Enforcement Administration (DEA) classified MDMA in Schedule I under the Controlled Substances Act. At the height of the drug war in 1985, the U.S. During this time, MDMA also began to be used recreationally under the name Ecstasy. Because of its remarkable therapeutic properties, it was used legally in therapy until 1985 by hundreds of therapists and psychiatrists. It was rediscovered in the 1970s by chemist Alexander Shulgin who shared it with Leo Zeff, a psychotherapist. “This is the remarkable story of Captain Al Hubbard-inventor, con man, secret agent, uranium entrepreneur, and indefatigable LSD apostle, who saw the light while high on psychedelics in the early 1950s and never looked back.” -Martin A.MDMA was first synthesized by Merck in 1912. Lee, author of Acid Dreams-The Complete Social History of LSD: The CIA, the Sixties, and Beyond “This is the remarkable story of Captain Al Hubbard-inventor, con man, secret agent, uranium entrepreneur, and indefatigable LSD apostle, who saw the light while high on psychedelics in the early 1950s and never looked back.” -Martin A. “An engaging biography about the mysterious Al Hubbard, who helped pioneer psychedelic therapy and is credited by Stan Grof with developing the model of the high dose inner-directed session to catalyze a mystical experience.” -Rick Doblin, PhD, founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS) Brilliantly told, Holden brings Hubbard’s enigmatic character to life.” -Erika Dyck PhD, Professor at the University of Saskatchewan, and author of Psychedelic Psychiatry: LSD from Clinic to Campus Holden dives into the larger-than-life history of a man whose past intersects with rum running, spy rings, police informants, and psychedelics. “A captivating history of one of America’s most colorful characters-Al Hubbard. Join author and historian Brad Holden as he chronicles the life of one of the most fascinating figures to emerge from Seattle’s past. In the early 1950s, after discovering the transformative effects of a little-known hallucinogenic compound, Hubbard would go on to become the “Johnny Appleseed of LSD,” paving the way for the very first generation of psychedelic disciples and beyond. From there, Hubbard transformed himself into a charlatan, bootlegger, radio pioneer, top-secret spy, millionaire and uranium entrepreneur. Hubbard made his first newspaper appearance with the announcement of a perpetual motion machine that harnessed energy from Earth’s atmosphere. In 1919, a mysterious young inventor named Alfred M. Seattle has a long tradition of being at the forefront of technological innovation. The biography of an intriguing man who came to Seattle as an inventor and went on to become a bootlegger, a spy, and a proponent of LSD.
0 Comments
Leave a Reply. |